CTeD has collaborated with the industry as well as entrepreneurs to successfully commercialise Duke-NUS’s technologies. The following are some examples of CTeD’s success stories:
CognaLearn is a learning-science company that uses InteLearn™, a proprietary patent-pending method developed at Duke-NUS Medical School, to optimise learning based on cognitive science. CognaLearn is the first internally incubated company at Duke-NUS, and it has generated over $1 million in revenue from its education solutions for GSK, Pfizer and Takeda. Its InteDashboard™ teaching software provides faculty real-time data at 20 institutions in Asia, Australia and the United States including Duke-NUS, Yale-NUS and the University of Florida. For more information on CognaLearn’s ongoing activities, please see:
www.cognalearn.com (holding company)
www.intedashboard.com (teaching software for team-based learning)
www.medniva.com (corporate solutions for the healthcare industry)
Vanteres (formerly known as Babynostics) is developing diagnostics and treatment solutions based on the research of Professor David Silver at Duke-NUS on MFSD2a and Lysophospatidylcholine (LPC) lipids. His key discovery was published in Nature on May 2014: ”Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid”.
Leveraging the knowledge of LPC physiology and pathophysiology, Vanteres is currently developing Diagnostic tests to aid in the identification of both subclinical and pathological alterations of LPC-lipids in a number of at risk populations. In addition Vanteres is currently developing a Gen 1.0 medical food product for commercialization and launch in 2017.
Vanteres’ current and future focus will be on the development of diagnostics tests and products that provide solutions that target the following areas with unmet medical needs:
- Prenatal support of mothers with high risk pregnancies.
- Preterm and/or small for gestational age infants.
- Cognitive development of infants and young children.
The press release issued by Duke-NUS on Vanteres is available via this link.
Enleofen Bio was founded as a spin-out from National Heart Centre Singapore (NHCS), SingHealth and Duke-NUS Medical School. Enleofen develops first-in-class antibody therapeutics for the treatment of fibrotic human diseases. Fibrotic disorders include diseases of the skin, lungs, heart, eye and kidneys and are a major health burden in Singapore and around the world.
The initial discovery science and drug target validation was carried out at NHCS and Duke-NUS by Professor Stuart Cook and Assistant Professor Sebastian Schafer. Over five patent applications and a number of advanced antibody and inhibitor drug candidates arising from the scientific work have been licensed to the company giving it a significant head start in drug development.
Enleofen Bio aims to have its lead antibody in clinical trials within a two year time frame with the goal of developing a drug that can be used to treat multiple diseases for which there are currently no treatment options.
The press release issued by Duke-NUS on Enleofen Bio is available via this link.
Travecta is an emerging biotech company utilizing its novel Blood-Brain Barrier Transport Platform to develop a proprietary pipeline of molecules that treat disorders of the central nervous system. The Travecta Platform leverages our proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents to the brain. Our platform and know-how allow us to identify and categorize small molecules for enabling their transport across the blood-brain barrier (BBB). Additionally, Travecta partners with pharmaceutical companies to apply our platform and assist them in overcoming the challenges associated with delivering drugs across the BBB. Travecta’s process allows partners to rapidly confirm BBB transport through feasibility studies that generate in vitro and in vivo transport data of their molecule generated with Travecta’s proprietary models.
Travecta was founded by experienced scientific leaders from Duke-NUS and received its initial seed-funding from TKS1, a healthcare and life science focused VC fund formed by the partnership between SPRIM Ventures and Tikehau Capital. We have offices in Philadelphia, PA and Singapore.
The press release issued by Duke-NUS on Travecta is available via this link.
Evecxia Therapeutics is a privately funded, clinical stage pharmaceutical company. In 2018, Evecxia licensed a jointly owned IP developed by Duke-NUS, NTU and NUH, which strengthens its existing patent portfolio. Under this license agreement, Evecxia has obtained exclusive, world-wide rights to develop and commercialize novel formulations for improving the bioavailability and pharmacokinetics of 5-Hydroxytryptophan (5-HTP) which is the precursor of the neurotransmitter serotonin. Using this joint IP, and IP previously licensed from Duke University, Evecxia is currently developing its lead drug candidate, EVX-101, which is a unique and proprietary oral slow-release formulation of 5-HTP and low-dose carbidopa for treatment of depression and other neurological disorders.
The press release issued by Evecxia highlighting the licensing of Duke-NUS-NTU-NUH IP is available via this link.
Neurobit Technologies is a Singapore-based start-up company co-founded by Dr. Amiya Patanaik, a former Duke-NUS Research Fellow, and another colleague. While working for Duke-NUS, in Professor Michael Chee’s lab, Dr. Patanaik and colleagues co-invented a real-time automatic sleep scoring system that uses recent advances in machine learning to automatically stage sleep data. The company was established in July 2018 to commercialize this technology. Recently, the company has developed an in-house sleep analytics technology, and their focus has shifted towards using their technology to make a personalized device-agnostic physiological data analytics platform. The founders are currently raising seed funds to carry out further development of this platform for treatment of sleep apnea.
To learn more about Neurobit Technologies, please see this link.
The idea of this SARS-nCov-2 Detection kit was conceived by a team led by Professor Wang Linfa, director of Duke-NUS' emerging infectious diseases programme at Duke-NUS in February 2020 and co-developed with GenScript Biotech Corporation, a leading biotech company, and the Agency for Science, Technology and Research's (A*STAR) Diagnostics Development Hub (DxD Hub). The Centre of Technology, Duke-NUS filed a patent application very rapidly and then, with very collaborative spirit on both sides successfully negotiated and executed the licence with GenScript within a month of filing. GenScript and DxD hub did an excellent job of meeting the regulatory requirements and launching the kit within two weeks of signing the deal. This Covid-19 test kit was the first of its kind to detect specific neutralizing antibodies that are harnessed by the body against the specific coronavirus infection. The test results are received in hours, as opposed to the usual several days.
cPass can be used:
- For contact tracing;
- For reservoir or intermediate animal tracking;
- For assessment of herd immunity;
- To see what population has been infected; and
- To see if potential vaccines are effective.
Unlike other Covid-19 tests for such antibodies, the test using cPass can be carried out in most research or clinical labs and doesn’t require working with live viruses or carrying out the operations in biosafety labs.